RxDoctor Payments DataLook up a doctor →

Mark Barakat, MD

Ophthalmology · Scottsdale, AZNPI 1225214646

Payments from drug & device makers

$2,946,920in general payments, 2019–2025

Across 1,295 payments — averaging $2275.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$903K
  • Ocular Therapeutix, Inc.$503K
  • Novartis$470K
  • Roche TCRC, Inc.$159K
  • Genentech USA, Inc.$133K
  • Astellas Pharma US Inc$125K
  • plus $654K from 45 others
$41,842in research payments, 2019–2025

Across 22 payments — averaging $1901.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$20K
  • Ocular Therapeutix, Inc.$10K
  • F. Hoffmann-la Roche AG$7K
  • Novartis Pharma AG$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.143$903,174
Ocular Therapeutix, Inc.111$502,642
Novartis112$470,014
Roche TCRC, Inc.15$159,498
Genentech USA, Inc.141$132,701
Astellas Pharma US Inc112$124,747
Eyepoint US, Inc.27$94,122
Boehringer Ingelheim8$89,263
Apellis Pharmaceuticals, Inc.84$72,908
F. Hoffmann-la Roche AG19$71,114
Novartis Pharma AG8$52,531
Bausch & Lomb Americas Inc.76$43,535
Regeneron Healthcare Solutions, Inc.73$40,813
Janssen Research & Development, LLC10$31,659
Hoffmann-la Roche Limited7$25,595
Regeneron15$19,624
Astellas Pharma Global Development8$18,124
Mylan Technologies Inc.56$16,811
AbbVie(2 entities)45$14,878
Alimera Sciences, Inc.54$11,501
Biogen10$10,761
Alcon21$7,902
Bausch & Lomb, A Division Of Bausch Health US, LLC16$6,035
Alcon Research LLC3$4,650
Boehringer Ingelheim International GmbH33$3,450
Neurotech Pharmaceuticals, Inc.4$3,260
Harrow Eye, LLC14$3,185
ANI Pharmaceuticals, Inc.7$2,722
Sanofi US Services Inc.1$2,037
Mylan Inc.1$1,776
Notal Vision, Inc.31$1,487
Coherus Oncology, Inc.3$1,400
Janssen Global Services, LLC3$1,059
Glaukos Corporation4$495
Rxsight Inc2$239
Dutch Ophthalmic, USA2$233
Eyevance Pharmaceuticals LLC1$171
Portola Pharmaceuticals, LLC1$129
Ivantis, Inc1$109
Carl Zeiss Meditec USA, Inc.2$108
Topcon Healthcare, Inc.1$107
Dompe US, Inc.1$95
Heidelberg Engineering, Inc.1$68
Mallinckrodt Hospital Products Inc.1$36
Samsara Vision1$35
Johnson & Johnson1$22
Lumibird Medical Inc.1$21
Spark Therapeutics, Inc.1$19
Boston Scientific1$18
Merge Healthcare Incorporated1$18
Genmab U.S., Inc.1$18

How this compares

$2,946,920 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona →

Medicare billing

Part B allowed, 2024
$1,703,932
Medicare patients
452
Services billed
120,670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Scottsdale

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →